Dural venous sinus thrombosis is not significantly associated with COVID-19 or non-COVID vaccines in a large, multi-state health care system.

DOI: https : //doi.org/10.1016/j.jstrokecerebrovasdis.2021.105923

Commentary

This study investigated the association of dural venous sinus thrombosis (CVST) in COVID-19 and non-COVID-19 vaccines.

It is a retrospective analysis of a cohort of 771,805 vaccination events in 266,094 patients at Mayo Clinic Health System from January 1, 2017 to March 15, 2021.

Results identified vaccination events for all FDA-approved COVID-19 vaccines, including Pfizer-BioNTech (n = 94,818 doses), Moderna (n = 36,350 doses), and Johnson & Johnson-J&J (n = 1,745 doses), and identified vaccination events for 10 common FDA-approved non-COVID-19 vaccines (n = 771,805 doses).

They stated that there is no statistically significant difference in the incidence of CVST in the 30 days before and after vaccination of vaccines in this population, and that the baseline CVST incidence in the study population from 2017 to 2021 is 45 to 98 per million patient-years. In conclusion, it is stated that the results of this study show that there is no significant difference in the association between COVID-19 vaccination and CVST.